ABBV/ENTA decided to present data from all six registrational phase-3 trials at a single conference; some of the trials are still in progress—see #msg-92025068. The reason for presenting the six trials as a package is unclear; it could be to make a bigger splash on the HCV community or to conceal some of the data from competitors a little longer.
Market Data 
Markets 
AI
